A phase III FIGHT 302 study is currently being evaluated to use pemigatinib as a first-line treatment in comparison with gemcitabine and cisplatin in patients with unresectable or metastatic CCA and FGFR2 alterations (fusions/rearrangements) [79,80]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.